Univariate and multivariate Cox regression analyses of survival of the selected French-EPO (n=284) and IMRAW (n=225) cohorts
| . | French-EPO, N=284, no. (%) . | IMRAW, N=225, no. (%) . | P for French-EPO vs IMRAW characteristics . | AML, French-EPO cohort, n=12 . | AML, IMRAW cohort, n=24 . | Died, French-EPO cohort, n=35 . | Died, IMRAW cohort, n=123 . | 5-year OS, % (± SD) . | Multivariate analysis of OS . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjusted HR . | 95% CI . | P . | |||||||||
| Age, y | |||||||||||
| Younger than 70 | 127 (45) | 130 (58) | — | 5 | 13 | 20 | 75 | 38 (5.1) | 1.1 | 0.8-1.5 | .53 |
| 70 or older | 157 (55) | 95 (42) | .003 | 7 | 11 | 15 | 48 | 55 (5.1) | 1 | — | — |
| Sex | |||||||||||
| Male | 157 (55) | 124 (55) | — | 6 | 17 | 25 | 74 | 37 (5.0) | 1 | — | — |
| Female | 127 (45) | 101 (45) | .97 | 6 | 7 | 10 | 49 | 57 (5.3) | 0.6 | 0.5-0.9 | .004 |
| FAB | |||||||||||
| RA | 111 (39) | 121 (54) | — | 3 | 9 | 16 | 65 | 43 (5.1) | 1 | — | — |
| RARS | 110 (39) | 70 (31) | — | 6 | 8 | 9 | 33 | 61 (6.1) | 0.6 | 0.4-0.8 | — |
| RAEB | 63 (22) | 34 (15) | .003 | 3 | 7 | 10 | 25 | na | 1.9 | 1.0-3.8 | .002 |
| Karyotype | |||||||||||
| Intermediate | 28 (10) | 35 (16) | — | 0 | 5 | 3 | 18 | 51 (10.9) | 1 | — | — |
| Favorable | 256 (90) | 190 (84) | .05 | 12 | 19 | 32 | 105 | 45 (3.9) | 0.9 | 0.6-1.5 | .84 |
| BM blasts,median (IQR)* | 3 (2-5) | 2 (1-4) | <.001 | — | — | — | — | — | 1.0 | 0.9-1.1 | .89 |
| IPSS | |||||||||||
| Low | 136 (48) | 78 (35) | — | 4 | 4 | 17 | 34 | 56 (5.7) | — | — | — |
| Int-1 | 148 (52) | 147 (65) | .003 | 8 | 20 | 18 | 89 | 40 (4.7) | — | — | — |
| Hb level, g/L | |||||||||||
| Less than 8 (80 g/L) | 150 (53) | 99 (44) | 9 | 14 | 20 | 57 | — | — | — | — | |
| 8 to 10 (80 to 100 g/L | 134 (47) | 126 (56) | .05 | 3 | 10 | 15 | 66 | — | — | — | — |
| rEPO treatment | |||||||||||
| Yes | 284 (100) | 0 (0) | — | — | — | — | — | 64 (8.1) | 0.43 | 0.25-0.72 | — |
| No | 0 (0) | 225 (100) | — | — | — | — | — | 39 (3.9) | 1 | — | .005 |
| . | French-EPO, N=284, no. (%) . | IMRAW, N=225, no. (%) . | P for French-EPO vs IMRAW characteristics . | AML, French-EPO cohort, n=12 . | AML, IMRAW cohort, n=24 . | Died, French-EPO cohort, n=35 . | Died, IMRAW cohort, n=123 . | 5-year OS, % (± SD) . | Multivariate analysis of OS . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjusted HR . | 95% CI . | P . | |||||||||
| Age, y | |||||||||||
| Younger than 70 | 127 (45) | 130 (58) | — | 5 | 13 | 20 | 75 | 38 (5.1) | 1.1 | 0.8-1.5 | .53 |
| 70 or older | 157 (55) | 95 (42) | .003 | 7 | 11 | 15 | 48 | 55 (5.1) | 1 | — | — |
| Sex | |||||||||||
| Male | 157 (55) | 124 (55) | — | 6 | 17 | 25 | 74 | 37 (5.0) | 1 | — | — |
| Female | 127 (45) | 101 (45) | .97 | 6 | 7 | 10 | 49 | 57 (5.3) | 0.6 | 0.5-0.9 | .004 |
| FAB | |||||||||||
| RA | 111 (39) | 121 (54) | — | 3 | 9 | 16 | 65 | 43 (5.1) | 1 | — | — |
| RARS | 110 (39) | 70 (31) | — | 6 | 8 | 9 | 33 | 61 (6.1) | 0.6 | 0.4-0.8 | — |
| RAEB | 63 (22) | 34 (15) | .003 | 3 | 7 | 10 | 25 | na | 1.9 | 1.0-3.8 | .002 |
| Karyotype | |||||||||||
| Intermediate | 28 (10) | 35 (16) | — | 0 | 5 | 3 | 18 | 51 (10.9) | 1 | — | — |
| Favorable | 256 (90) | 190 (84) | .05 | 12 | 19 | 32 | 105 | 45 (3.9) | 0.9 | 0.6-1.5 | .84 |
| BM blasts,median (IQR)* | 3 (2-5) | 2 (1-4) | <.001 | — | — | — | — | — | 1.0 | 0.9-1.1 | .89 |
| IPSS | |||||||||||
| Low | 136 (48) | 78 (35) | — | 4 | 4 | 17 | 34 | 56 (5.7) | — | — | — |
| Int-1 | 148 (52) | 147 (65) | .003 | 8 | 20 | 18 | 89 | 40 (4.7) | — | — | — |
| Hb level, g/L | |||||||||||
| Less than 8 (80 g/L) | 150 (53) | 99 (44) | 9 | 14 | 20 | 57 | — | — | — | — | |
| 8 to 10 (80 to 100 g/L | 134 (47) | 126 (56) | .05 | 3 | 10 | 15 | 66 | — | — | — | — |
| rEPO treatment | |||||||||||
| Yes | 284 (100) | 0 (0) | — | — | — | — | — | 64 (8.1) | 0.43 | 0.25-0.72 | — |
| No | 0 (0) | 225 (100) | — | — | — | — | — | 39 (3.9) | 1 | — | .005 |
SD indicates standard deviation; HR, hazard ratio; and —, not applicable.
indicates interquartile range.